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Introduction {#sec001}
============

Allergic rhinitis (AR) is a common inflammatory disorder generally caused by an immunoglobulin (Ig) E-mediated response to a variety of environmental allergens, including cockroach frass, animal dander, pollens, dust mites, and molds \[[@pone.0228533.ref001]\]. It is characterized by two or more symptoms of nasal itching, rhinorrhea, nasal congestion, and/or sneezing \[[@pone.0228533.ref002]\]. AR has been reported to have an adverse impact on sleep, memory ability, quality of life, academic performance, and work productivity \[[@pone.0228533.ref003]--[@pone.0228533.ref007]\]. In 2010, AR affected 10%--20% of the worldwide population, and that number continues to grow with modern lifestyle and environmental changes \[[@pone.0228533.ref001]\]. It is estimated that AR results in 3.4 billion dollars of direct medical costs annually \[[@pone.0228533.ref008]\].

Sleep is crucial for human mood, memory, endocrine and immune system functions, and cognition \[[@pone.0228533.ref009]--[@pone.0228533.ref014]\]. Poor sleep quality, sleep disorders, and/or inadequate sleep duration are considered to be triggers for the development of hypertension \[[@pone.0228533.ref015]\], diabetes \[[@pone.0228533.ref016]\], obesity \[[@pone.0228533.ref017]\], cardiovascular disease \[[@pone.0228533.ref018]\], and increased mortality \[[@pone.0228533.ref019]\]. AR has been shown to be an important factor in altered sleep patterns in previous studies \[[@pone.0228533.ref007]\].

There is a growing body of population-based research on the association between AR and sleep patterns. AR has been found to be positively associated with sleep- disordered breathing (SDB) \[[@pone.0228533.ref020]\], obstructive sleep apnea (OSA) \[[@pone.0228533.ref021]\], shorter sleep duration \[[@pone.0228533.ref022]\], poor sleep quality \[[@pone.0228533.ref023]\], sleep bruxism \[[@pone.0228533.ref024]\], night sweating \[[@pone.0228533.ref025]\], nocturnal enuresis \[[@pone.0228533.ref026]\], and daytime dysfunction \[[@pone.0228533.ref027]\]. However, these results are also controversial, since several studies found a negative or insignificant relationship between AR and the above sleep-related outcomes \[[@pone.0228533.ref007], [@pone.0228533.ref028]--[@pone.0228533.ref030]\]. Currently, there is a lack of systematic reviews to evaluate the association between AR and sleep pattern through meta-analysis.

Thus, the present study aims to assess the association of AR with sleep pattern by conducting a systematic review and meta-analysis of published observational studies.

Materials and methods {#sec002}
=====================

This systematic review and meta-analysis was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement \[[@pone.0228533.ref031]\].

Search strategy {#sec003}
---------------

Cross-sectional, case-control, and cohort studies examining associations between AR and sleep published before August 2019 were searched in the following databases: PubMed, Embase, and CINAHL. Combinations of sleep-related search terms ("sleep", "insomnia", "somnolence", or "snoring") and AR-related search terms ("rhinitis", "rhino conjunctivitis", "nasal allergy", or "hay fever") were employed when screening titles/abstracts/keywords of articles. The full electronic search strategy can be found in the [S1 File](#pone.0228533.s029){ref-type="supplementary-material"}. Studies that met the inclusion criteria were retrieved for a full-text review, unless the article was unavailable even after every attempt at retrieval. To reduce potential selection bias, each article was independently evaluated by two of the investigators (J.L. and Y.W.), and the final decision to include/exclude was made jointly with a third investigator (Y.Z.) according to the basic inclusion criteria.

Inclusion criteria {#sec004}
------------------

The following inclusion criteria were applied to the literature search process: (1) cross-sectional, case-control, or cohort studies published in refereed English language journals; (2) the study exposure of interest was AR; (3) for studies comparing differences in sleep (sleep quality score, sleep duration, or incidence of adverse sleep events) between AR and a control group, the outcomes were reported as mean + standard deviation (SD), mean + confident interval (CI), mean + standard error (SE), median + interquartile (IQ), median + range, or number of cases with adverse events; (4) for studies evaluating the effect of AR on sleep-related outcomes, estimation of an odds ratio (OR), risk ratio (RR), or hazard ratio (HR) with 95% CI was provided; and (5) study control group was a population without AR.

Data extraction {#sec005}
---------------

Data extraction was performed using a standard data extraction form by one investigator (J.L.) and reviewed by another investigator (Y.W.). Disagreements were resolved through negotiations with a third investigator (Y.Z.) until a consensus was reached. The following information was extracted from included studies: title, last name of the first author, country, number and age of subjects, exposure and outcome, measures of exposure and research endpoints, mean + SD/CI/SE, median + IQ/range, number of cases, and HR/OR/RR with 95% CI.

Assessment of study quality {#sec006}
---------------------------

The quality of studies included in this review were assessed by the Newcastle-Ottawa Scale (NOS) \[[@pone.0228533.ref032]\]. A study was defined as high quality if the total stars were six or greater.

Statistical analysis {#sec007}
--------------------

We treated HRs as RRs and converted RRs into ORs \[[@pone.0228533.ref033]\]. Median and CI/SE/IQ/range were converted into mean + SD in accordance with guidelines laid down by Wan *et al* \[[@pone.0228533.ref034]\]. For studies providing continuous data for comparative analysis between AR and control groups, pooled mean difference (MD) with 95% CI was used as the effect size. Pooled OR with 95% CI was used to evaluate studies reporting OR/RR/HR with 95% CI. Random effects model was used to incorporate included studies \[[@pone.0228533.ref035]\]. We also performed a fixed effects model to compare studies \[[@pone.0228533.ref036]\], and the results of this fixed effects model can be found in [S1](#pone.0228533.s001){ref-type="supplementary-material"}--[S5](#pone.0228533.s005){ref-type="supplementary-material"} Figs. Statistical heterogeneity was assessed by the I^2^-heterogeneity test \[[@pone.0228533.ref037]\], with an I^2^ \> 50% indicating high heterogeneity. To evaluate the effects of different study designs on pooled estimates, we performed a subgroup analysis stratified by study design for outcomes with enough included studies. Subgroup analysis stratified by age, patients with OSA, study design, and measurement of outcome was also conducted for sleep duration. For meta-analysis of three or more studies, we omitted one study each time and then calculated the pooled result in order to detect the impact of any one study on the overall results. Since it is suggested that tests for funnel plot asymmetry should be used only when there are at least 10 studies included in the meta-analysis for adequate power, we did not perform the funnel plot or Egger's test to evaluate publication bias \[[@pone.0228533.ref038]\]. All statistical analyses were performed through the "meta" package of R software (R Foundation for Statistical Computing, Vienna, Austria).

Assessment of cumulative evidence {#sec008}
---------------------------------

A summary of the overall strength of available evidence was performed using the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) assessment \[[@pone.0228533.ref039]\]. Evidence summaries and GRADE assessments were discussed and reviewed by all investigators. A Summary of Findings table was produced by GRADEpro software (McMaster University, Hamilton, Canada) \[[@pone.0228533.ref040]\].

Results and discussion {#sec009}
======================

Literature search and study characteristics {#sec010}
-------------------------------------------

[Fig 1](#pone.0228533.g001){ref-type="fig"} presents the literature search and selection process. 2544 records published before August 2019 were identified. After title, abstract, keyword, and full-text screening, 27 articles were included. The [S1 Table](#pone.0228533.s022){ref-type="supplementary-material"} lists studies that superficially met the eligibility criteria during full-text screenings; however, failed to meet the criteria on further inspection.

![Flow diagram of the literature search and selection processes.](pone.0228533.g001){#pone.0228533.g001}

The characteristics of included studies are summarized in [Table 1](#pone.0228533.t001){ref-type="table"}. A total of 240,706,026 patients (19,444,043 AR cases) were included from 13 cross-sectional studies, 10 case-control studies, and 4 cohort studies. Both adult and pediatric patients were included. Medical records, clinical examination findings, skin prick test results, self-reported questionnaires, and face-to-face interviews were reviewed to confirm AR. Sleep--related outcomes were collected and confirmed by medical records, clinical examination findings, self-reported questionnaires, polysomnography (PSG) results, actigraphy results, and face-to-face interviews.

10.1371/journal.pone.0228533.t001

###### Characteristics of included studies.

![](pone.0228533.t001){#pone.0228533.t001g}

  Study                           Age                  Sample size/AR cases   Study type        Measurement-AR                                               Measurement-sleep outcome   Outcomes
  ------------------------------- -------------------- ---------------------- ----------------- ------------------------------------------------------------ --------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Roxbury *et al*., 2018          45.6 (44.0--47.11)   5556/1797              Cross-sectional   Self-reported                                                Self-reported               Sleep duration, SDB, snoring, OSA, insomnia, restless sleep, use of sleeping pills, daytime dysfunction
  Loekmanwidjaja *et al*., 2018   4--10                167/112                Case-controlled   Medical records                                              Self-reported               Sleep duration, daytime sleepiness
  Lai *et al*., 2018              \<18                 655529/327928          Cohort            Medical records                                              Medical records             OSA, nocturnal enuresis
  Filiz *et al*., 2018            8--18                287/143                Cross-sectional   Medical records, clinical examination, and skin prick test   Face-to-face interview      Sleep duration, restless sleep, PSQI outcomes, daytime dysfunction
  Zhou *et al*., 2017             47±0.2               240000000/19100000     Cross-sectional   Self-reported                                                Self-reported               Sleep duration
  Zheng *et al*., 2017            18--70               171/65                 Cross-sectional   Medical records, clinical examination, and skin prick test   PSG                         Sleep duration, OSA, PSG outcomes
  Tsai *et al*., 2017             5--18                8516/4191              Case-controlled   Medical records, clinical examination                        Medical records             Nocturnal enuresis
  Nguyen-Hoang *et al*., 2017     9.5±2.1              85/52                  Case-controlled   Clinical examination                                         Medical records             OSA
  Kim *et al*., 2017              68.3±5.6             348/57                 Cross-sectional   Self-reported                                                PSG                         SDB, PSG outcomes, PSQI outcomes
  Hui *et al*., 2017              49.61±16.27          1028/-                 Cross-sectional   Medical records                                              Medical records             OSA
  Di *et al*., 2016               3--14                135/57                 Case-controlled   Medical records, clinical examination, and skin prick test   PSG                         PSG outcomes
  Trikojat *et al*., 2015         18--45               83/41                  Case-controlled   Medical records, clinical examination, and skin prick test   Self-reported               Sleep duration, PSQI outcomes, daytime dysfunction
  Poachanukoon *et al*., 2015     10.6±2.5             175/65                 Case-controlled   Medical records, clinical examination, and skin prick test   Self-reported               Sleep duration, difficult waking up, snoring, morning headache, mouth breathing, night sweating, nocturnal enuresis, OSA daytime sleepiness, restless sleep, SDB, sleep bruxism
  Ng *et al*., 2014               15.3±1.7             175/65                 Cohort            Self-reported                                                Self-reported               Snoring
  Cai *et al*., 2013              \-                   1993/123               Cross-sectional   Medical records                                              Self-reported               OSA
  Zhang *et al*., 2012            46.3±5.1             2291/211               Cohort            Self-reported                                                Self-reported               Restless sleep
  So *et al*., 2012               9.2 (7.7--10.7)      6381/2661              Cross-sectional   Self-reported                                                Self-reported               Night sweating
  Park *et al*., 2012             20--68               112/37                 Case-controlled   Clinical examination and skin prick test                     PSG and self-reported       Sleep duration, AHI, PSG outcomes, ESS
  Meng *et al*., 2011             18--60               128/98                 Case-controlled   Self-reported                                                PSG                         PSG outcomes
  Li *et al*., 2010               5--14                6369/2823              Cross-sectional   Self-reported                                                Self-reported               Snoring
  Rimmer *et al*., 2009           \>18                 20/10                  Case-controlled   Self-reported                                                Actigraphy                  Sleep duration
  Hiraki *et al*., 2008           39.4±9.6             852/112                Cross-sectional   Self-reported                                                Self-reported               Daytime sleepiness, snoring, ESS
  Dixon *et al*., 2006            ≥15                  1969/1133              Cohort            Self-reported                                                Self-reported               ESS, PSQI outcomes
  Sogut *et al*., 2005            8.1±1.9              992/332                Case-controlled   Self-reported                                                Self-reported               Snoring
  Ng *et al*., 2005               6--12                3047/1242              Cross-sectional   Self-reported                                                Self-reported               Daytime sleepiness, OSA
  Chng *et al*., 2004             4--7                 9362/674               Cross-sectional   Self-reported                                                Self-reported               Snoring
  Anuntaseree *et al*., 2001      7.25±0.58            255/14                 Cross-sectional   Self-reported                                                Self-reported               Snoring

AR: allergic rhinitis; ESS: Epworth Sleepiness Scale; HS: habitual snoring; NAR: non-allergic rhinitis; OSA: obstructive sleep apnea; PSG: polysomnography; PSQI: Pittsburgh Sleep Quality Index; REM: rapid eye movement; SDB: sleep-disordered breathing.

Comparative analyses of sleep outcomes between AR patients and controls {#sec011}
-----------------------------------------------------------------------

Nine studies reported sleep durations of AR and control groups. Pooled results showed no significant difference in sleep duration between the groups \[MD with 95% CI = 0.79 (-14.90, 16.48)\] with high heterogeneity (I^2^ = 93.00%). Subgroup analysis stratified by age, presence of OSA, study design, and measurement of sleep duration were conducted, but no significant differences were observed ([Fig 2](#pone.0228533.g002){ref-type="fig"}).

![Comparative analysis of sleep duration.\
AR: allergic rhinitis; CI: confidence interval; MD: mean difference; OSA: obstructive sleep apnea; PSG: polysomnography.](pone.0228533.g002){#pone.0228533.g002}

Four studies reported comparisons of Pittsburgh Sleep Quality Index (PSQI) scores in patients with AR. Compared with the control group, the AR group presented with higher sum PSQI scores \[MD with 95% CI = 0.68 (0.20, 1.15)\], higher sleep disturbances scores \[MD with 95% CI = 0.20 (0.13, 0.27)\], and higher sleep latency scores (MD with 95% CI = 0.29 (0.13, 0.45)). The I^2^ was 20.90% for the summed PSQI score and 0.00% for the sleep disturbance and sleep latency scores. Three studies provided comparisons of the Epworth Sleepiness Scale (ESS) in patients with AR. The AR group presented with a higher, though not significant, sum ESS score \[MD with 95% CI = 1.53 (-0.23, 3.30)\]. Five articles reporting PSG outcomes showed lower scores of sleep efficiency \[MD with 95% CI = -3.95 (-7.00, -0.45), I^2^ = 89.00%\] in the AR group ([Fig 3](#pone.0228533.g003){ref-type="fig"}).

![Comparative analysis of PSQI scale, ESS scale, and PSG outcomes.\
AHI: apnea-hypopnea index; ESS: Epworth Sleepiness Scale; PSQI: Pittsburgh Sleep Quality Index; REM: rapid eye movement.](pone.0228533.g003){#pone.0228533.g003}

Adjusted associations between AR and sleep outcomes {#sec012}
---------------------------------------------------

[Fig 4](#pone.0228533.g004){ref-type="fig"} shows the adjusted relationship between AR and sleep outcomes. Patients with AR were more likely to suffer from nocturnal sleep-related dysfunctions, including insomnia \[OR with 95% CI = 1.84 (1.07, 3.16)\], nocturnal enuresis \[OR with 95% CI = 1.75 (1.44, 2.13), I^2^ = 28.50%\], restless sleep \[OR with 95% CI = 2.20 (1.26, 3.82), I^2^ = 51.20%\], SDB \[OR with 95% CI = 3.55 (1.03, 12.31), I^2^ = 85.80%\], OSA \[OR with 95% CI = 2.09 (1.41, 3.10), I^2^ = 53.60%\], and snoring \[OR with 95% CI = 2.34 (1.68, 3.28), I^2^ = 83.40%\]. AR was also associated with a higher risk of daytime sleep-related dysfunctions, including difficulty waking up \[OR with 95% CI = 2.58 (1.36, 4.89)\], daytime sleepiness \[OR with 95% CI = 1.85 (1.14, 3.00), I^2^ = 53.20%\], morning headache \[OR with 95% CI = 6.16 (2.48, 15.27)\], and the use of sleeping pills \[OR with 95% CI = 1.69 (1.20, 2.38)\].

![Forest plot for adjusted associations between AR and sleep outcomes.\
AR: allergic rhinitis; CI: confidence interval; OR: odds ratio; OSA: obstructive sleep apnea; SDB: sleep-disordered breathing.](pone.0228533.g004){#pone.0228533.g004}

Evaluation of the effect of study design {#sec013}
----------------------------------------

We conducted subgroup analysis stratified by study design for sleep duration, apnea-hypopnea index (AHI), sleep efficiency measured by PSG, the percent of sleep stage REM measured by PSG, OSA, and snoring. Significant differences in results from different study designs were observed for AHI, sleep efficiency measured by PSG, and the percent of sleep stage REM measured by PSG, indicating the potential influence of study design on pooled results. Detailed information is shown in the supplemental material ([S6](#pone.0228533.s006){ref-type="supplementary-material"}--[S11](#pone.0228533.s011){ref-type="supplementary-material"} Figs).

Assessment of study quality and sensitivity analysis {#sec014}
----------------------------------------------------

Most of the included studies were of high quality according to the NOS criteria. Detailed information is shown in [S2](#pone.0228533.s023){ref-type="supplementary-material"}--[S4](#pone.0228533.s025){ref-type="supplementary-material"} Tables.

By omitting one study each time using a random effects model, sensitivity analysis was conducted for meta-analyses of sleep duration, ESS score, AHI assessed by PSG, sleep efficiency assessed by PSG, the percentage of sleep stage REM assessed by PSG, nocturnal enuresis, restless sleep, OSA, snoring, and daytime sleepiness. Pooled results of sleep duration and AHI assessed by PSG were significantly sensitive to the study of Zheng *et al* \[[@pone.0228533.ref030]\], because the direction of the synthesized MD changed after it was omitted. The results of the ESS score, sleep efficiency evaluated by PSG, nocturnal enuresis, restless sleep, and daytime sleepiness also showed instability. Detailed information is presented in [S12](#pone.0228533.s012){ref-type="supplementary-material"}--[S21](#pone.0228533.s021){ref-type="supplementary-material"} Figs.

Assessment of cumulative evidence {#sec015}
---------------------------------

The overall quality of evidence using GRADE's Summary of Findings table was judged to be low or very low. Risk of bias, inconsistencies (methodological, clinical, and statistical), indirectness, and imprecision were found due to lack of adjusting confounding factors, incorporation of different age groups and study designs, self-reported AR, and sleep outcomes. The Summary of Findings table can be found in [S5](#pone.0228533.s026){ref-type="supplementary-material"} and [S6](#pone.0228533.s027){ref-type="supplementary-material"} Tables.

In the present review, no significant differences in sleep duration between the AR and control groups were observed. AR patients presented with increased sleep quality scores, sleep disturbance scores, and sleep latency scores on the PSQI scale and a decreased sleep efficiency score using PSG. AR was also found to be associated with a higher risk of nocturnal sleep-related dysfunctions, including insomnia, nocturnal enuresis, restless sleep, SDB, OSA, and snoring. Additionally, AR was found to be associated with a higher risk of daytime sleep-related dysfunctions, including difficulty waking up, daytime sleepiness, morning headache, and the use of sleeping pills.

The main underlying mechanisms for the association between AR and altered sleep patterns can be summarized as follows: (1) inflammatory cytokines related to AR produce fatigue directly; (2) AR symptoms and underlying pathophysiologic changes affect sleep indirectly; and (3) the effect of autonomic system dysfunction in patients with AR.

Inflammatory mediators, including histamine, are released in AR and have a direct influence on the central nervous system, contributing to sleep disturbances and daytime sleepiness \[[@pone.0228533.ref041], [@pone.0228533.ref042]\]. Histamine can also affect the regulation of the sleep-wake cycle, which may result in arousal disorder \[[@pone.0228533.ref041], [@pone.0228533.ref043]\]. AR also induces decreased levels of the interleukins (ILs)-1β, IL-4, IL-6 and IL-10, which may increase REM sleep (important in the restorative function of sleep), decrease sleep onset latency, improve circadian rhythm, and regulate slow wave sleep \[[@pone.0228533.ref044]\]. These changes contribute to why patients with AR often have difficulties with overnight sleep and daytime tiredness.

Symptoms of AR include nasal congestion, rhinorrhea, sneezing, and pruritus. Among these symptoms, nasal obstruction is the most troublesome one for patients \[[@pone.0228533.ref045]--[@pone.0228533.ref047]\]. Nasal congestion is considered to be a major factor interfering with sleep quality and inducing daytime somnolence. Previous studies suggest that nasal obstruction contributes to higher risks of OSA \[[@pone.0228533.ref048]--[@pone.0228533.ref050]\] and SDB \[[@pone.0228533.ref051], [@pone.0228533.ref052]\]. The role of nasal congestion as a risk factor for snoring has also been confirmed by a population-based cohort study \[[@pone.0228533.ref053]\]. A negative effect of nasal congestion was also found on quality of life and daytime productivity \[[@pone.0228533.ref054], [@pone.0228533.ref055]\]. Data on sleep-related end points from clinical trials of nasal decongestants are associated with improved sleep, reduced daytime fatigue, and improved quality of life \[[@pone.0228533.ref056]\]. Other symptoms including cough and sputum production also contribute to poor sleep quality and sleep disorders \[[@pone.0228533.ref057], [@pone.0228533.ref058]\].

Imbalance of the autonomic system in AR is also thought to be involved to the association between AR and sleep impairment \[[@pone.0228533.ref059]\]. As one of the most powerful autonomic nerve reflexes, the trigeminocardiac reflex (TCR) is believed to directly influence the development of SDB, OSA, REM sleep apnea, and nasal congestion \[[@pone.0228533.ref060]--[@pone.0228533.ref062]\]. The nasotrigeminal reflex, a peripheral nervous system equivalent of the TCR, is also thought to have a potential influence on sleep impairment \[[@pone.0228533.ref060]\]. The extent of autonomic dysfunction in AR and sleep disturbances is still not well-established and needs further investigation.

To the best of our knowledge, this is the first systematic review and meta-analysis evaluating the association between AR and sleep based on observational investigations. A 2018 systematic review focused on the association between AR and OSA and applied a meta-analysis of population-based studies; however, this article concentrated mainly on the prevalence of AR in subjects with or without OSA/SDB \[[@pone.0228533.ref063]\]. Another related review examined AR and sleep impairment, but focused mainly on the mechanism of their association and the consequences of disordered sleep \[[@pone.0228533.ref064]--[@pone.0228533.ref071]\].

There are some limitations to the current study. First, most of the included studies are cross-sectional or case-controlled, which do not allow for inferences of causal relationships. Second, some results from this study's meta-analyses display sensitivity to a single study included in the analysis, potentially due to the limited number of included studies. In terms of the sensitivity analysis of sleep duration and AHI assessed by PSG, the inverse MD is caused by the study of Zheng *et al*., which was conducted in patients with OSA. We included a limited number of studies focusing on OSA patients and failed to detect a difference between the normal population and patients with OSA. More investigations conducted in patients with OSA are needed. Third, some outcomes of sleep impairment are confirmed by self-reported questionnaires, which are vulnerable to recall bias and potentially affected by social norms. Further longitudinal research with objective measurements are warranted.

Conclusions {#sec016}
===========

There is a significant association of AR with sleep characteristics; however, due to the very low GRADE level of evidence, caution is required when interpreting our results.

Supporting information {#sec017}
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